These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 11718560)

  • 21. Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing.
    Sugimoto M; Kuo ML; Roussel MF; Sherr CJ
    Mol Cell; 2003 Feb; 11(2):415-24. PubMed ID: 12620229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function.
    Korgaonkar C; Hagen J; Tompkins V; Frazier AA; Allamargot C; Quelle FW; Quelle DE
    Mol Cell Biol; 2005 Feb; 25(4):1258-71. PubMed ID: 15684379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mdm2 regulates p53 independently of p19(ARF) in homeostatic tissues.
    O'Leary KA; Mendrysa SM; Vaccaro A; Perry ME
    Mol Cell Biol; 2004 Jan; 24(1):186-91. PubMed ID: 14673154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. p14ARF expression in invasive breast cancers and ductal carcinoma in situ--relationships to p53 and Hdm2.
    Vestey SB; Sen C; Calder CJ; Perks CM; Pignatelli M; Winters ZE
    Breast Cancer Res; 2004; 6(5):R571-85. PubMed ID: 15318938
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.
    Stott FJ; Bates S; James MC; McConnell BB; Starborg M; Brookes S; Palmero I; Ryan K; Hara E; Vousden KH; Peters G
    EMBO J; 1998 Sep; 17(17):5001-14. PubMed ID: 9724636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of a novel nucleophosmin-interaction motif in the tumor suppressor p14arf.
    Luchinat E; Chiarella S; Franceschini M; Di Matteo A; Brunori M; Banci L; Federici L
    FEBS J; 2018 Mar; 285(5):832-847. PubMed ID: 29283500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma.
    Mori S; Ito G; Usami N; Yoshioka H; Ueda Y; Kodama Y; Takahashi M; Fong KM; Shimokata K; Sekido Y
    Cancer; 2004 Apr; 100(8):1673-82. PubMed ID: 15073856
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growth suppression by a p14(ARF) exon 1beta adenovirus in human tumor cell lines of varying p53 and Rb status.
    Saadatmandi N; Tyler T; Huang Y; Haghighi A; Frost G; Borgstrom P; Gjerset RA
    Cancer Gene Ther; 2002 Oct; 9(10):830-9. PubMed ID: 12224024
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p14(ARF) regulates E2F activity.
    Mason SL; Loughran O; La Thangue NB
    Oncogene; 2002 Jun; 21(27):4220-30. PubMed ID: 12082609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
    Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T
    Clin Cancer Res; 2003 Oct; 9(13):4884-90. PubMed ID: 14581362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway.
    Brady SN; Yu Y; Maggi LB; Weber JD
    Mol Cell Biol; 2004 Nov; 24(21):9327-38. PubMed ID: 15485902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ARF tumor suppression in the nucleolus.
    Maggi LB; Winkeler CL; Miceli AP; Apicelli AJ; Brady SN; Kuchenreuther MJ; Weber JD
    Biochim Biophys Acta; 2014 Jun; 1842(6):831-9. PubMed ID: 24525025
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p14ARF interacts with N-Myc and inhibits its transcriptional activity.
    Amente S; Gargano B; Diolaiti D; Della Valle G; Lania L; Majello B
    FEBS Lett; 2007 Mar; 581(5):821-5. PubMed ID: 17289033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CARF (collaborator of ARF) interacts with HDM2: evidence for a novel regulatory feedback regulation of CARF-p53-HDM2-p21WAF1 pathway.
    Hasan MK; Yaguchi T; Harada JI; Hirano T; Wadhwa R; Kaul SC
    Int J Oncol; 2008 Mar; 32(3):663-71. PubMed ID: 18292944
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MdmX inhibits ARF mediated Mdm2 sumoylation.
    Ghosh M; Weghorst K; Berberich SJ
    Cell Cycle; 2005 Apr; 4(4):604-8. PubMed ID: 15876864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular characterization of the hdm2-p53 interaction.
    Böttger A; Böttger V; Garcia-Echeverria C; Chène P; Hochkeppel HK; Sampson W; Ang K; Howard SF; Picksley SM; Lane DP
    J Mol Biol; 1997 Jun; 269(5):744-56. PubMed ID: 9223638
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Further insight into substrate recognition by USP7: structural and biochemical analysis of the HdmX and Hdm2 interactions with USP7.
    Sarkari F; La Delfa A; Arrowsmith CH; Frappier L; Sheng Y; Saridakis V
    J Mol Biol; 2010 Oct; 402(5):825-37. PubMed ID: 20713061
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor.
    Chen D; Kon N; Li M; Zhang W; Qin J; Gu W
    Cell; 2005 Jul; 121(7):1071-83. PubMed ID: 15989956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple sites of in vivo phosphorylation in the MDM2 oncoprotein cluster within two important functional domains.
    Hay TJ; Meek DW
    FEBS Lett; 2000 Jul; 478(1-2):183-6. PubMed ID: 10922493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2.
    Kamijo T; Weber JD; Zambetti G; Zindy F; Roussel MF; Sherr CJ
    Proc Natl Acad Sci U S A; 1998 Jul; 95(14):8292-7. PubMed ID: 9653180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.